Parkinson’s Researchers Identify Mechanism Involved in Memory Degeneration
The abnormal alpha-synuclein characteristic of Parkinson’s disease interacts with the prion protein PrP, initiating a series of events that culminate…
Articles by Alice Melão
Common Antidepressant Also Delays Parkinson’s Disease Progression, MSU Researchers Show
The antidepressant drug nortriptyline — approved more than 50 years ago for depression and nerve pain — may also slow…
Free Water Molecules in Brain Region Could Help Track Parkinson’s Progression, Study Suggests
Quantifying changes in fluid in a specific brain area, using a magnetic resonance imaging (MRI)-based method, could provide a way to track…
Mouse Study Identifies Processes Responsible for Loss of Touch, Smell in Parkinson’s
Researchers at the Karolinska Institute in Sweden have identified the underlying neural mechanisms responsible for the reduced sense of touch and…
Computer Games Under Study as Non-Drug Therapy for Parkinson’s Disease
Researchers from North Wales received a £33,000 (about $43,000) award to study the potential benefits…
Phase 1 Study of Voyager’s Gene Therapy Shows Potential for Parkinson’s Patients
The latest result from Voyager Therapeutic’s Phase 1 clinical trial on gene therapy (VY-AADC01) for advanced Parkinson’s disease shows early promise…
U.S. OKs 23andME Testing the Public for Risk of Parkinson’s, Other Genetic Diseases
23andMe Inc. has become the first company to receive U.S. approval to market genetic tests that can flag patients on…
Treatment to Prevent Transplant Rejection Seen to Hold Promise in Parkinson’s Study
A treatment widely used to help prevent rejection in organ transplants, called tacrolimus, appears to work to treat Parkinson’s disease (PD)…
Mitochondrial DNA Damage May Be Involved in Parkinson’s Disease Neurodegeneration
In recent decades studies have shed new light on Parkinson’s disease (PD), but the cause of the neurodegenerative disease is…
New Therapy for Parkinson’s ‘Off’ Periods Shows Promising Results in Preclinical Studies
CVT-301, an inhalable drug under development by Acorda Therapeutics to treat Parkinson’s symptoms during “off” periods when currently available drugs don’t adequately…